[{"orgOrder":0,"company":"Berlin Chemie","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dalteparin sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Phase III","graph3":"Berlin Chemie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Berlin Chemie \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Berlin Chemie \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Damoctocog Alfa Pegol","moa":"Coagulation factor VIII","graph1":"Hematology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Hematology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Hematology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Hematology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Idarucizumab","moa":"Dabigatran","graph1":"Hematology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Idarucizumab","moa":"Dabigatran","graph1":"Hematology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Idarucizumab","moa":"Dabigatran","graph1":"Hematology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Idarucizumab","moa":"Dabigatran","graph1":"Hematology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fresenius Kabi AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius Kabi AG \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fresenius Kabi AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius Kabi AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Molidustat","moa":"HIF-PH||Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 1 | Egl nine homolog 3","graph1":"Hematology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Molidustat","moa":"HIF-PH||Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 1 | Egl nine homolog 3","graph1":"Hematology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Molidustat","moa":"HIF-PH||Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 1 | Egl nine homolog 3","graph1":"Hematology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Molidustat","moa":"HIF-PH||Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 1 | Egl nine homolog 3","graph1":"Hematology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Molidustat","moa":"HIF-PH||Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 1 | Egl nine homolog 3","graph1":"Hematology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Molidustat","moa":"Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 1 | Egl nine homolog 3","graph1":"Hematology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Molidustat","moa":"Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 1 | Egl nine homolog 3","graph1":"Hematology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Molidustat","moa":"Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 1 | Egl nine homolog 3","graph1":"Hematology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Molidustat","moa":"Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 1 | Egl nine homolog 3","graph1":"Hematology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Molidustat","moa":"Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 1 | Egl nine homolog 3","graph1":"Hematology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Molidustat","moa":"Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 1 | Egl nine homolog 3","graph1":"Hematology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Molidustat","moa":"Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 1 | Egl nine homolog 3","graph1":"Hematology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Molidustat","moa":"Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 1 | Egl nine homolog 3","graph1":"Hematology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dabigatran Etexilate Mesylate","moa":"Thrombin","graph1":"Hematology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dabigatran Etexilate Mesylate","moa":"Thrombin","graph1":"Hematology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
